A new study will investigate the long-term safety and effects of the experimental treatment buntanetap in people with Parkinson’s disease, according to Annovis Bio, the therapy’s developer. The open-label extension (OLE) study (NCT07284784) is expected to enroll about 500 adults with Parkinson’s disease, ages 40 to 85,…
News
Zambon Biotech has dosed the first patient in its clinical trial testing Crexont (IPX203) — an extended-release formulation of carbidopa/levodopa (CD/LD) that aims to ease so-called off episodes — among people with advanced Parkinson’s disease. With several locations now open in Italy, Poland, and Spain, the Phase…
Throughout 2025, the team at Parkinson’s News Today has reported on the latest research updates and advances in care related to Parkinson’s disease. Below is a list of the top 10 most-read articles we published this year. We look forward to continuing to serve as a source of news…
Aerobic exercise triggers a surge of dopamine in the brain that can significantly improve movement and coordination during the aging process, a new study in mice suggests. By providing “neurochemical evidence” for the benefits of staying active, researchers found that regular physical activity can help offset the natural decline of…
GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of people with Parkinson’s disease. Results from a Phase 1b trial (NCT06732180) show that approximately three months of treatment with GT-02287 was safe and led to a robust reduction…
The Michael J. Fox Foundation (MJFF) has awarded a $1 million research grant to MODAG to advance new PET imaging tools aimed at detecting Parkinson’s disease earlier and more accurately. Specifically, the funding will support the clinical development of MODAG-009, a PET tracer designed to measure…
Stress may be linked to higher levels of inflammation in people with Parkinson’s disease, according to a new analysis of data collected during the COVID-19 pandemic. The findings were reported in the study, “The interplay between stress, inflammation and Parkinson’s disease: insights from the COVID-19 pandemic,”…
Biotechnology company Ophidion is teaming up with Neuronasal, a clinical-stage company focused on nose-to-brain delivery of therapies for central nervous system disorders, to develop ways to deliver treatments for Parkinson’s disease and other conditions to the brain using noninvasive technology. The companies said…
Kenai Therapeutics said the first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of RNDP-001, its experimental cell replacement therapy for Parkinson’s disease. The REPLACE trial (NCT07106021) is recruiting up to 12 people with moderate to severe idiopathic (of unknown cause)…
Three research teams investigating five high-potential targets for new Parkinson’s disease therapies received initial funding under a multi-year initiative from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grants are the first to be awarded under MJFF’s Targets to Therapies Initiative, which aims to advance the…
Recent Posts
- Late-onset depression may foreshadow Parkinson’s diagnosis
- Being mad at each other and mad at Parkinson’s disease, too
- Parkinson’s muscle firing patterns different for women than for men
- Breathing CO2 activates brain cleanup signals in new Parkinson’s study
- Guest Voice: DBS surgery transformed my life with early-onset Parkinson’s